AZoNetwork, the leading authority in scientific marketing, recently generated a record 33% increase in first 6-month sales. This peak performance punctuated the company’s thirtieth consecutive quarter of year-on-year growth in a marketplace where many traditional agencies are continuing to struggle.
Despite ongoing geo-economic uncertainty, AZoNetwork has concentrated on expansion and internal investment which has proven critical in sustaining an upward growth trajectory. This included expanding the team’s headcount by up to 40% and relocating to a new Bruntwood office in Manchester city…
Following on from the success of the Marketing Science Roadshow last year, AZoNetwork have released new venues and dates for their Marketing Science programme.
The Marketing Science roadshow aims to educate Sales & Marketing professionals working within the Science, Healthcare and Engineering industries.
Check out our upcoming dates:
Oxford Science Park - Wednesday 13th February
Manchester SEO Workshop - Wednesday 20th February
Nottingham Biocity - Wednesday 6th March
Marketing Science Webinar - Thursday 7th March
Pittcon - Marketing Science in 2019 - Wednesday 20th March
Marketing…
BioCity, the UK’s largest life science incubator has been appointed by Newcastle City Council to run a life science accelerator and business support programme from The Biosphere, which is based on Newcastle Helix.
The programme is being delivered by BioCity from The Biosphere, a brand new purpose-built 90,000 sq. ft commercial lab and office facility located on Newcastle Helix.
BioCity will focus on creating and growing small businesses, through the acceleration of entrepreneurial activity and the commercialisation of ideas within life sciences. The overall aim is to…
Wickham Laboratories Ltd is delighted to announce our most recent technical article on, “Microbiological Considerations in Cleanroom Validation”, which has been featured in European Pharmaceutical Review’s December 2018 issue.
Microbiological contamination is a major safety concern within the manufacturing and development of all pharmaceutical & medical devices. This article discusses how and why a cleanroom environment plays an important role during these processes.
An excerpt of this article as follows:
CLEANROOMS and other controlled environments play a vital role in manufacturing and…
Boyds, a leading consultancy business supporting the development of pharmaceutical and biotech products for patient benefit, has set up a Clinical and Medical Affairs Group to provide pharmaceutical medicine and medical monitoring support to its clients and their programmes.
Dr Lalitha Mahadavan has been appointed as Director of Clinical and Medical Affairs and will head up the Cambridge-based Group, which will provide a multi-speciality consulting service to Boyds’ client portfolio.
Lalitha is a Consultant in Pharmaceutical Medicine (GMC Registered) and a Fellow of the Faculty of…
The RSA Group, a leading Life Sciences executive search firm, announced today that Mark Johnson has joined the company as a Partner. Mark is a respected life sciences search professional with particular expertise in the cell and gene therapy sector.
Mark has significant experience across medical, manufacturing and supply chain, commercial, R&D, CMC, Clinical Operations, Regulatory and Programme / Project Leader recruitment. This stems from an early career in biologics development, manufacturing and quality at MedImmune and Novartis. Most recently he has focused on cell and gene therapy…
Cambridge, UK, 04 February 2019: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that ModernaTX, Inc. (NASDAQ: MRNA) has exercised its option to enter into an exclusive licensing agreement with respect to certain Affimers against a potential therapeutic target that has been part of an ongoing research collaboration between the two companies.
In 2015, Avacta and Moderna entered into a collaboration, license and option agreement under which Moderna was granted exclusive access to Avacta’s Affimer technology for certain collaboration…
Tokyo, Japan and London, UK, 4 February 2019 – Sosei Group Corporation (“the Company”; TSE: 4565), announces it has entered into a structured financing agreement1 with Medicxi, a venture fund dedicated to financing asset-centric companies, to form two independent companies, Orexia Limited (“Orexia”) and Inexia Limited (“Inexia”), that aim to develop novel therapies based on positive modulators of the G protein-coupled receptors Orexin OX1 and OX2 for neurological diseases. Medicxi will be investing in both companies with an aggregate amount of up to €40 million.
Under the terms of…
PRINCETON, NJ – Jan. 29, 2019 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced the launch of version 18 of its Simcyp® Population-based Simulator.
“I am delighted to introduce Simcyp Simulator v18, which includes several major modeling and simulation advances to help improve the safety and efficacy of new drugs – both small molecules and biologics – under development,” said Certara’s Simcyp President and Managing Director Steve Toon, PhD.
“When we began developing the Simcyp Simulator 20…